Antibodies targeting ccr2
AssigneeGranite Bio AG
InventorMatthias Mack
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to antibodies and antibody fragment that are specific for CCR2. The antibodies deplete CCR2-positive cells and block MCP-1 (CCL2) induced downregulation of CCR2 on human leukocytes. Furthermore, they possess advantageous biophysical properties. The antibodies are useful for the treatment of inflammatory diseases, autoimmune diseases, hematologic malignancies and potentially other illnesses.
Claims25
A method of inhibiting CCR2-induced chemotaxis in a subject in need thereof comprising administering a therapeutically effective amount of an antibody or antibody fragment that specifically binds to human CCR2, wherein the antibody or antibody fragment comprises a VH comprising HCDR1, HCDR2, and HCDR3, and a VL comprising LCDR1, LCDR2, and LCDR3, wherein the HCDR1, HCDR2, and HCDR3 comprise the HCDR1, HCDR2, and HCDR3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO:
- 22;
- and wherein the LCDR1, LCDR2, and LCDR3 comprise the LCDR1, LCDR2, and LCDR3 of the VL amino acid sequence set forth in SEQ ID NO:
- 23.
A polypeptide comprising a VH comprising the HCDR1, HCDR2, and HCDR3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO:
- 22.
A polypeptide comprising a VL comprising the LCDR1, LCDR2, and LCDR3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO:
- 23.
Dependencies are inferred from the claim text.